News & Updates

People with irritable bowel syndrome (IBS) are not at increased overall risk of cancer relative to the general population, reveals a study. On the contrary, those with IBS appear to have a lower risk of incident colorectal cancer (CRC) and cancer-specific mortality.

Frailty is associated with a higher relative risk of 30-day complications, 1-year mortality, and repeat procedures for persistent incontinence or obstructed voiding at 1 year after sling surgery in older adults, suggests a recent study.

In a phase II trial evaluating three doses of the high-affinity cereblon modulator iberdomide, the 0.45-mg dose demonstrated superiority over placebo for individuals with active, moderate-to-severe systemic lupus erythematosus (SLE).

Helicobacter pylori eradication treatment leads to large reductions in the risk of gastric cancer and lower rates of associated deaths over 10 years of follow-up, according to a recent meta-analysis.

A recent cross-sectional questionnaire study has shown that women with postmenopausal bleeding (PMB) would select transvaginal sonography to measure endometrial thickness (TVS-ET) over gold-standard hysteroscopy with biopsy if TVS-ET achieved a median endometrial cancer detection rate of 95.0 percent.

Treatment with tenapanor improves symptoms in patients with irritable bowel syndrome with constipation (IBS-C) as early as week 1 of treatment, according to two phase III studies presented at DDW 2022.